Connect with us

BUSINESS

Constellation Brands, Inc. (NYSE: STZ) Invests in HOP WTR and Southern Copper Corp (NYSE: SCCO) Increases Dividend to $0.90

Published

on

One of the largest alcohol companies, Constellation Brands, Inc. (NYSE: STZ), bought a few stakes in HOP WTR, a non-alcohol company producing calorie-free water imparted with nootropics and adaptogens to provide a balanced flavor for health-centric customers. Constellation’s Venture Capital Group secured these minority stakes; however, HOP WTR remains the independent owner and will manage and produce its brand and products as usual. 

New Space for Constellation

The Vice President of Constellation Ventures, Jennifer Evans, said, “the non-alcoholic beverage company is becoming famous among the health conscious consumer preferences in this era. She also praised Nick and Jordan for taking this new approach aiming at consumer health and by making this investment Constellation will learn what awaits them in this fast growing space.”

A Fast Growing Sector

The non-alcoholic beverage sector is rapidly growing in the last few years; it gained a 37% growth in 2020. In recent research conducted by IWSR, it’s evident that 58% of consumers are switching to low-alcoholic or non-alcoholic beverages.

Nick Taranto and Jordan Bass founded HOP WTR in 2020. Their primary goal is to produce a calorie-free beer alternative that gives the same feel or function. In sparkling bubbly water pervaded with centennial dry hops, Columbus, and citrus, HOP WTR adds nootropics and adaptogens, ashwagandha and L-theanine.

Dividend Increases

Southern Copper Corp (NYSE: SCCO) announced that it would be increasing its dividend to $0.90 on August 26. So, the dividend price ratio will become 4.2% which is higher than the industry average. A large dividend yield will mean nothing if the company cannot sustain it. 

Fortunately, Southern Copper’s profits last year prove that it can cover the dividend. It stipulates, a large number of profits is reinvested into the business. Earnings per share are expected to increase by 15.8% next year. Along with trends, if the dividend manages to grow means the estimated payout will reach 83% on the top side, but still possible.

The company grew its distributions rate by 5.2% yearly. Dividends have grown at reasonable and practical rates, but this stock will not be ideal to live on this income with one substantial cut in payments.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BUSINESS

Innovative Industrial Properties Inc (NYSE: IIPR) Broadens its Real Estate Partnership Agreement with Harvest

Published

on

Innovative Industrial Properties Inc (NYSE: IIPR), which isn’t just the first but also the only real estate corporation on the NYSE (New York Stock Exchange, focuses on the regulation of the United States cannabis industry. The company recently announced that it had acquired a certain property in Maryland. Innovative Properties also announced that it had executed a long-term lease agreement with one of Harvest Health’s subsidiaries.

The company acquired the product for roughly $16.6 million. The Harvest subsidiary is expected to conduct additional tenant improvements on the property to be deemed a regulated cannabis processing and cultivation facility. Innovative Properties has agreed to reimburse Harvest up to around $12.9 million for this particular project. Innovative Properties will be putting in a total investment of roughly $29.5 million when you add the tenant improvement reimbursement. Innovative properties also acquired another property in Florida earlier this year.

Senior Management 

Innovative Properties’ Chief Executive Officer and President, Paul Smithers, said they were delighted to be expanding their Harvest long-term real estate partnership further. He claimed that Harvest has continued to execute on its business plan very well so far, and has a huge vertical footprint in some of the United States’ strongest, most robust cannabis markets. He claimed that they’re looking forward to collaborating closely with Harvest as they expand their production efforts further in Maryland so that they can meet the ever-growing demand in the region.

The medical-use cannabis program in Maryland was implemented about three years ago in 2017. In the initial implementation stage, It had limited licenses to dispense, process and cultivate cannabis. Medical conditions that qualify for the program include chronic pain, anorexia, seizures, PTSD, severe nausea and persistent o severe muscle spasms. Just like in other states in the US, the regulatory authorities in this state have broadened the program over time. They now allow doctors and their assistants to recommend medical marijuana use if they think it’ll help with treatments.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Neutra Corp (OTCMKTS: NTRR) Continues to Secure Distribution for VIVIS’ CBD-based Products

Published

on

Neutra Corp (OTCMKTS: NTRR) continues to make great progress when it comes to securing distribution solutions for its VIVIS’ CBD-based products. Since the company announced what it was planning in January, Neutra’s management team has managed to ensure VIVIS products are on shelves in Festival Foods, a gigantic 35 store supermarket chain in the region.

The company is also delighted to collaborate with another west coast retail chain for its distribution purposes. The retail chain’s name and specifics about the agreement will be announced later when the product is on the shelves. The national sales team at VIVIS is still in several different discussions involving distribution with many other regional and nationwide retail chains.

Other distribution projects 

The management team at Neutra is also discussing with distributors who are outside online and traditional brick-and-mortar sales channels. These other parties typically have international exposure and household name recognition. Specifics of the deals will be announced later because of obvious competitive reasons. However, management says that they believe in the potential of this strategy and are very optimistic it will bear fruit.

Lastly, the management team has also communicated with a specific clinical research organization that could be up for sale soon. This would help give Neutra another revenue stream and also allow them to do clinical research backing of their products in-house. The team has found significant and cleared synergies between both businesses.

Senior Management

The company’s Chief Executive Officer, Sydney Jim, said they continue to witness an increased demand for CBD-based VIVIS products across the country. In addition, he claimed that the traction of the company’s sales team has also increased since it started engaging different distributors earlier this year. Mr. Jim said that they hope to announce good news soon as well as bring value to their shareholders.

VIVIS’s holding company, Neutra Corp, is an initial-stage R&D company that focuses on bringing healthy, modern living options to this particular market. Cutting-edge tech food and drug, environmental purification, and nutraceuticals sectors are helping give rise to a new global culture where consumers want healthier products.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Cash and Investments on Hand of $114M in the Q2 2021 Financial Results Announced by Corbus Pharmaceuticals Holdings, Inc (NASDAQ: CRBP) Provides Projected Runway into Q1 of 2024

Published

on

Corbus Pharmaceuticals Holdings, Inc (NASDAQ: CRBP) has put in so much investment In its purpose of improving people’s lives. The company develops new medicines, which target immuno-oncology, metabolism, fibrosis, and inflammation. The Massachusetts headquartered entity has released its Q2 2021 financial results, which showcase a net loss of approximately $17.1 million. And while Q2 2020 recorded roughly $286,000 in revenue from awards and licenses, Q2 2021 recorded $137,000.

However, according to the company’s CEO, Yuval Cohen, they had a strong position in cash and investment at the hand of approximately $114M. The company would use this to advance its diversified portfolio. In addition, the recent licensing of two integrin-targeting mAbs is already making significant progress concerning expansion. 

DETERMINE Phase 3 Study of Lenabasum Produces Topline Results 

In other news, a Phase 3 DETERMINE study of lenabasum in adults with autoimmune disease dermatomyositis did not meet its primary endpoint of Total Improvement Score (TIS) at Week 28. However, the Chief Medical Officer, Barbara White, says despite the discouraging results, the management was encouraged by the fact that they matched to the subtype of dermatomyositis in the study. 

Enrolled subjects would have to demonstrate classic dermatomyositis with muscle weakness. Also, they had to have skin involvement or dermatomyositis with no significant muscle weakness but with skin involvement. 

Dermatomyositis reportedly affects approximately 80,000 people in North America, the EU, and Japan. The sometimes life-threatening autoimmune disease is chronic, rare, clinically heterogeneous, and inflammatory. Distinctive skin rashes alongside proximal muscle weakness, pulmonary, cardiac, gastrointestinal, and joint involvements are primary signs and symptoms. 

Unfortunately, there is a significant unmet need for the proper treatment for dermatomyositis disease. The present-day treatment is the systemic glucocorticoids approved by the FDA. And there is also the off-label use of glucocorticoid-sparing immunosuppressive. On the other hand, lenabasum provides an alternative to immunosuppressive treatments for inflammatory or fibrotic diseases. The novel, oral, small-molecule activates the cannabinoid receptor type 2 (CB2) to resolve inflammation. 

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories